丙戊酸镁缓释片联合碳酸锂治疗躁狂发作临床分析.docVIP

丙戊酸镁缓释片联合碳酸锂治疗躁狂发作临床分析【摘要】 目的 探讨丙戊酸镁缓释片联合碳酸锂与碳酸锂治疗躁狂发作的疗效与安全性。方法 将52例符合中国精神障碍分类与诊断标准第3版(CCMD-3)躁狂发作诊断标准的患者随机分为研究组(26例)和对照组(26例),研究组应用丙戊酸镁缓释片、碳酸锂以及非典型抗精神病药物利培酮。对照组应用碳酸锂联合与利培酮治疗,疗程6周。用躁狂评定量表(BRMS)与副反应量表(TESS)分别评定疗效及不良反应观察6周。结果 研究组和对照组6周治疗后与治疗前的BRMS评分差异均具有统计学意义(P0.05)。结论 丙戊酸镁缓释片联合碳酸锂控制躁狂发作的疗效优于碳酸锂治疗,安全性良好。? 【关键词】 丙戊酸镁缓释片； 碳酸锂； 躁狂发作?? Magnesium valproate sustained-release tablets plus lithium in treatment of manic episodes of clinical MU Xiao-mei，WEI Zhang-li，ZHANG Zi-ming， HONG Gui-zi，WANG Xiu-mei.Tianshui the Third People?s Hospital of Tianshui City,Tianshui 741000,China? 【Abstract】 Objectve Magnesium valproate tablets of lithium carbonate and lithium carbonate in treatment of joint manic episode of the efficacy and safety.Methods 52 patients met the Chinese Classification and Diagnostic Criteria of Mental Disorders Version 3 (CCMD-3) diagnostic criteria for manic episode were randomly divided into study group (26 cases) and control group (26 cases),Application of magnesium valproate group sustained release tablets,lithium and atypical antipsychotic risperidone.Control group were combined lithium and risperidone,treatment 6 w.Mania rating scale used (BRMS) and the side effects scale (TESS) assessed the efficacy and adverse reactions were observed for 6 weeks.Results The study group and control group after 6 weeks of treatment before treatment BRMS score differences were statistically significant(P0.05).Conclusion The magnesium valproate combined lithium carbonate controlled release tablets manic episode is better than lithium in treatment efficacy,security is good.? 【Key Words】 Magnesium valproate tablets； Lithium carbonate； Manic episode ?? 长期以来,一般都是采用心境稳定剂联用抗精神病药物治疗作为躁狂发作的治疗方案,这样可以比较快速地控制躁狂发作［1］。由于人们对经典抗精神病药物潜在的严重不良反应的顾虑,在治疗急性躁狂或有精神病性症状的躁狂发作中使用新型抗精神病药物越来越广泛。尽管通过联合治疗,但实际临床上仍有相当一部分患者不能在短期内取得良好的效果,因此还需要联合一种心境稳定剂。为了探讨丙戊酸镁缓释片联合碳酸锂与碳酸锂治疗躁狂发作的疗效与安全性，我们进行了本研究。? 1 资料与方法? 1.1 一般资料 为来自笔者所在医院2008年2月~2010年8月的连续门诊就诊及住院患者。入组标准:（1）符合中国精神障碍分类与诊断标准第3版(CCMD-3